{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:38:37Z","timestamp":1787164717125,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1053\/j.ajkd.2019.08.032","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T22:49:58Z","timestamp":1575413398000},"page":"288-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report"],"prefix":"10.1053","volume":"76","author":[{"given":"In\u00e8s","family":"Dufour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quitterie","family":"Venot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selda","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Demoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Canaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Morelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9751","key":"10.1053\/j.ajkd.2019.08.032_bib1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2019.08.032_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.06.026","article-title":"Antiphospholipid syndrome and kidney disease","volume":"91","author":"Bienaime","year":"2017","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2019.08.032_bib3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3389\/fimmu.2018.01181","article-title":"Antiphospholipid syndrome nephropathy: from pathogenesis to treatment","volume":"9","author":"Tektonidou","year":"2018","journal-title":"Front Immunol"},{"key":"10.1053\/j.ajkd.2019.08.032_bib4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fimmu.2018.01008","article-title":"Renal involvement in antiphospholipid syndrome","volume":"9","author":"Turrent-Carriles","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.ajkd.2019.08.032_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2019.08.032_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2017.01.002","article-title":"A\u00a0proposal for standardized grading of chronic changes in native kidney biopsy specimens","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2019.08.032_bib7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.ajkd.2019.08.032_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"9","key":"10.1053\/j.ajkd.2019.08.032_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1053\/j.ajkd.2019.08.032_bib10","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/jth.13475","article-title":"Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism","volume":"14","author":"Arachchillage","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1053\/j.ajkd.2019.08.032_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V103507","article-title":"The intrarenal vascular lesions associated with primary antiphospholipid syndrome","volume":"10","author":"Nochy","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2019.08.032_bib12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3899\/jrheum.170561","article-title":"Early renin-angiotensin system blockade improved short-term and longterm renal outcomes in systemic lupus erythematosus patients with antiphospholipid-associated nephropathy","volume":"45","author":"Yue","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1053\/j.ajkd.2019.08.032_bib13","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1600-6143.2010.03233.x","article-title":"Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2019.08.032_bib14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm.3313","article-title":"AKT2 is essential to maintain podocyte viability and function during chronic kidney disease","volume":"19","author":"Canaud","year":"2013","journal-title":"Nat Med"},{"issue":"suppl 8","key":"10.1053\/j.ajkd.2019.08.032_bib15","first-page":"viii61","article-title":"Sirolimus in renal transplantation","volume":"22","author":"Morath","year":"2007","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619310613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619310613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:28:40Z","timestamp":1759462120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638619310613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0272638619310613"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.08.032","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}